The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Autor:	E. Gez, Howard I. Scher, Gedske Daugaard, Brieuc Sautois, Josep M. Piulats, Simon Paul Watkins, Wassim Abida, Laurence Eliot Miles Krieger, Charles J. Ryan, Andrew Simmons, Florence Joly, Raymond S. McDermott, Alejo Rodriguez-Vida, Cora N. Sternberg, K. Fizazi, S. Shetty, T. Golsorkhi, J.A. Arranz Arija, Srikala S. Sridhar, Simon Chowdhury, Axel S. Merseburger, Axel Heidenreich, Jeremy Shapiro
Rok vydání:	2017
Předmět:	Oncology medicine.medical_specialty Pathology business.industry Urology Castration resistant medicine.disease Clinical trial Prostate cancer chemistry.chemical_compound chemistry Internal medicine PARP inhibitor medicine In patient Rucaparib Homologous Recombination Deficiency business
Zdroj:	European Urology Supplements. 16:e2689-e2690
ISSN:	1569-9056
DOI:	10.1016/s1569-9056(17)31836-5
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3a39a3f95ca1ab9d1debd9ed8bdf0e69 https://doi.org/10.1016/s1569-9056(17)31836-5 Zobrazit plný text záznamu Full Text from ScienceDirect